(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
4 November 2010 (04.11.2010)

PCT

(10) International Publication Number
WO 2010/125003 A1

(51) **International Patent Classification**:
C07K 16/28 (2006.01) ***A61K 39/395*** (2006.01)

(21) **International Application Number**:
PCT/EP2010/055458

(22) **International Filing Date**:
23 April 2010 (23.04.2010)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
61/173,004 27 April 2009 (27.04.2009) US
61/306,137 19 February 2010 (19.02.2010) US

(71) **Applicant** *(for all designated States except US)*: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(72) **Inventors; and**

(75) **Inventors/Applicants** *(for US only)*: **BERGER, Catrin** [DE/DE]; Kriegerstr. 72, 82110 Germering (DE). **HERRMANN, Tanja** [DE/DE]; Georg-Hager-Str. 4, 81369 München (DE). **LU, Chris** [US/CN]; China Novartis Institutes for, BioMedical Research Co., Ltd., No. 8 Building, Lane 898 Halei Road, Zhangjiang Hi-Tech Park Pudong New Area Shanghai 201203 (CN). **SHEPPARD, Kelly-Ann** [US/US]; Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US). **TRIFILIEFF, Estelle** [FR/CH]; Novartis Pharma AG, Postfach, CH-4002 Basel (CH). **URLINGER, Stefanie** [DE/DE]; Asternstrasse 12, 80689 München (DE).

(74) **Agent**: **SPINNER, David, Richard**; Novartis Pharma Ag, Patent Department, CH-4002 Basel (CH).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*

— *with (an) indication(s) in relation to deposited biological material furnished under Rule 13bis separately from the description (Rules 13bis.4(d)(i) and 48.2(a)(viii))*

— *with sequence listing part of description (Rule 5.2(a))*

WO 2010/125003 A1

(54) **Title**: COMPOSITIONS AND METHODS FOR INCREASING MUSCLE GROWTH

(57) **Abstract**: This invention is in the field of anti-Activin receptor IIB (ActRIIB) antibodies. In particular, it relates to the use of said antibodies for treating muscle disorders, such as muscle wasting due to disease or disuse.